Table 1.
Participant baseline characteristics
| Characteristics | Values |
|---|---|
| Age (years), median (IQR) | 54.5 (42.5–62) |
| Sex, female/male, n (%) | 38 (63)/22 (37) |
| Indication for apremilast, n (%) | |
| PsA | 56 (93) |
| Psoriasis | 4 (7) |
| Disease duration, years, median (IQR) | |
| PsA | 7.8 (1.8–11.9) |
| Psoriasis | 14.7 (6.8–23.3) |
| Smoking status, n (%) | |
| Current smoker | 13 (22) |
| Ex-smoker | 15 (25) |
| Non-smoker | 31 (52) |
| Not stated | 1 (2) |
| Anthropometry, median (IQR) | |
| Weight, kg | 93.0 (75.8–107.2) |
| BMI, kg/m2 | 33.2 (26.8–40.0) |
| Waist circumference, cm | 103.5 (95–120) |
| Hip circumference, cm | 113 (102.5–127) |
| Waist:hip ratio | 0.93 (0.88–0.98) |
| Systolic BP (mmHg) | 132 (120–146) |
| Diastolic BP (mmHg) | 78 (70–84) |
| Comorbidities, n (%) | |
| Hypertension | 13 (21.7) |
| Type 2 diabetes | 4 (6.7) |
| Dyslipidaemia | 6 (10.0) |
| Liver diseasea | 4 (6.7) |
| Medications, n (%) | |
| Anti-hypertensive agents | 14 (23.3) |
| Lipid-lowering therapy | 8 (13.3) |
| Oral anti-diabetic agentsb | 1 (1.7) |
| Concomitant DMARD | 11 (18.3) |
a
Liver disease consisted of n = 2 non-alcoholic fatty liver disease, n = 1 alcoholic liver disease and n = 1 liver fibrosis and cyst. bExcluding DPP-IV inhibitors.